These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32105171)

  • 21. Pharmaceutical policy and the pharmacy profession.
    Traulsen JM; Almarsdóttir AB
    Pharm World Sci; 2005 Oct; 27(5):359-63. PubMed ID: 16341741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.
    Academia EC; Mejías-De Jesús CM; Stevens JS; Jia LY; Yankama T; Patel C; Lee J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1438-1446. PubMed ID: 34595953
    [No Abstract]   [Full Text] [Related]  

  • 23. Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy.
    Peter ME; Markley B; DeClercq J; Choi L; Givens G; Zuckerman AD; Banks A
    J Manag Care Spec Pharm; 2021 Feb; 27(2):256-262. PubMed ID: 33506731
    [No Abstract]   [Full Text] [Related]  

  • 24. Designing and implementing an effective specialty pharmacy service program.
    Morrow TJ
    Manag Care Interface; 2003 Apr; 16(4):50-3. PubMed ID: 12747141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IACP's 2016 Compounders on Capitol Hill Asks.
    Int J Pharm Compd; 2016; 20(4):294-296. PubMed ID: 28333674
    [No Abstract]   [Full Text] [Related]  

  • 26. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.
    Vu TM; Toribio W; Riazi F; Ciprian G; Gibbs N; Giardina M; Camacho JA; Parrella K; Cambe J; Amory C; Chasan R; Sigel KM; Weiss JJ
    J Manag Care Spec Pharm; 2018 Apr; 24(4):329-333. PubMed ID: 29578854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specialty pharmacy presents unique set of challenges.
    Lotvin A
    Manag Care; 2004 Aug; 13(8):8-9. PubMed ID: 15457888
    [No Abstract]   [Full Text] [Related]  

  • 28. Implementing California Senate Bill 493 in an Outpatient Pharmacy Within an Integrated Health System: Evaluation of the Operational and Clinical Effect of Pharmacist-Ordered Laboratory Tests.
    Delgado HM; Kleinman NP; Makarem AF; Nguyen C
    J Manag Care Spec Pharm; 2020 Mar; 26(3):320-324. PubMed ID: 32105181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications for pharmacy from the Institute of Medicine's report on Health Care Workforce and an Aging America.
    Gray SL; Elliott D; Semla T
    Ann Pharmacother; 2009 Jun; 43(6):1133-8. PubMed ID: 19417109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Internet pharmaceutical sales: attributes, concerns, and future forecast.
    Bruckel K; Capozzoli EA
    J Hosp Mark Public Relations; 2003; 15(1):61-76. PubMed ID: 15683019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Tiered Pharmacy Benefit: Challenges in Today's Health Care Market.
    Kenney JT
    J Manag Care Spec Pharm; 2020 May; 26(5):586-587. PubMed ID: 32347178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
    Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
    J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Curtiss FR; Fry RN; Avey SG
    J Manag Care Spec Pharm; 2020 Jul; 26(7):798-816. PubMed ID: 32584678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Intersection of Implementation Science and Pharmacy Practice Transformation.
    Smith MA; Blanchard CM; Vuernick E
    Ann Pharmacother; 2020 Jan; 54(1):75-81. PubMed ID: 31353925
    [No Abstract]   [Full Text] [Related]  

  • 35. The outlook for pharmacist initiation and modification of drug therapy.
    Shefcheck SL; Thomas J
    J Am Pharm Assoc (Wash); 1996 Oct; NS36(10):597-604. PubMed ID: 8908936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration.
    Richard C; Urick BY; Pathak S; Jackson J; Livet M
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1568-1578. PubMed ID: 34714107
    [No Abstract]   [Full Text] [Related]  

  • 37. APhA federal pharmacy initiatives: supporting those in harm's way.
    Tackitt RD
    J Am Pharm Assoc (2003); 2007; 47(5):566. PubMed ID: 17848341
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of prescription reimbursement methodologies in Japan and the United States.
    Akaho E; MacLaughlin EJ; Takeuchi Y
    J Am Pharm Assoc (2003); 2003; 43(4):519-26. PubMed ID: 12952317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The "Lists": What Do They Mean?
    Voliva J
    Int J Pharm Compd; 2016; 20(6):477-479. PubMed ID: 28339386
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
    Motheral BR; Fairman KA
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.